NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00532194,An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer,https://clinicaltrials.gov/study/NCT00532194,ICON6,UNKNOWN,"The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.",NO,Ovarian Cancer,DRUG: cediranib,"Progression-free survival, Apr 2013","Overall survival, Q2 2016|Toxicity, Q2 2015|Quality of Life, Q2 2015",,Medical Research Council,"Cancer Research UK|National Health and Medical Research Council, Australia|Australia New Zealand Gynaecological Oncology Group|NCIC Clinical Trials Group|Grupo Español de Investigación en Cáncer de Ovario|AstraZeneca",FEMALE,"ADULT, OLDER_ADULT",PHASE3,486,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-001346-41|ISRCTN68510403|2007-001346-41,2007-07,2013-04,2016-12,2007-09-20,,2015-09-23,"University College London, London, Greater London, WC1E 6BT, United Kingdom",
